“Smarter” CAR T Cells Target Tumors with Precision
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
“Smarter” CAR T Cells Target Tumors with Precision
“Smarter” CAR T Cells Target Tumors with Precision
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Researchers employ peripheral blood mononuclear cells (PBMCs) in clinical and academic applications related to the immune system and regenerative medicine.
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers.
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.